Comparison of fetuin‐A and transforming growth factor beta 1 levels in patients with spondyloarthropathies and rheumatoid arthritis

Harman, Halil; Tekeoğlu, İbrahim; Gürol, Gönül; Sağ, Mustafa Serdar; Karakeçe, Engin; Çiftçi, İhsan Hakkı; Kamanlı, Ayhan; Nas, Kemal

doi:10.1111/1756-185x.12791

Cited by 12 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study conducted in RA patients showed a non-significant increase in this molecule in the serum of patients compared to healthy controls [39], however our study is the first to evaluate levels of TGFβ1 in the early RA phase. We showed a significant increase in TGFβ1 that may have a compensatory effect in response to increased inflammatory state.…”

Section: Resultsmentioning

confidence: 80%

Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study

Buondonno¹,

Rovera

Sassi³

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

The aim of this study was to evaluate differences in T helper cell sub-types and osteoclast (OCs) precursors in peripheral blood between patients affected by early rheumatoid arthritis (eRA) and healthy controls. The effect of administration of cholecalcipherol on clinical and laboratory parameters was subsequently evaluated, by a parallel, randomized double blind, placebo controlled trial. Thirty nine eRA patients and 31 age-matched controls were enrolled and compared for levels of 25OH vitamin D, T helper cell sub-types, OCs precursors including both classical and non-classical and pro-inflammatory cytokines at baseline. Eligible patients were female ≥18 years of age with a diagnosis of RA, as defined by the American College of Rheumatology 2010 criteria for <6 months prior to inclusion in the study. Patients with auto-immune or inflammatory diseases other than RA were excluded. Patients treated with glucocorticoids (GCs), disease modifying activity drugs and biologic agents within the past 6 months were also excluded. In the second phase of the study, eRA patients were randomly assigned to standard treatment with methotrexate (MTX) and GCs with (21) or without (18) cholecalcipherol (300,000 IU) and followed for 3 months; the randomization was done by computer generated tables to allocate treatments. Three patients didn’t come back to the follow up visit for personal reasons. None of the patients experienced adverse events. The main outcome measures were T cells phenotypes, OCs precursors and inflammatory cytokines. Secondary outcome measure were clinical parameters. In eRA, 25OH vitamin D levels were significantly lower. CD4+/IFNγ+,CD4+/IL4+, CD4+/IL17A+ and CD4+IL17A+IFNγ+, cells were increased in eRA as well as non-classical OCs precursors, whereas T regulatory cells were not altered. TNFα, TGFβ1, RANKL, IL-23 and IL-6 were increased in eRA. Non-classical OCs, IL-23 and IL-6 correlated with disease severity and activity. Standard treatment with MTX and GC ameliorated clinical symptoms and reduced IL-23, whereas it did not affect CD4+ cells sub-sets nor OCs precursors. After 3 months, the combined use of cholecalcipherol significantly ameliorated the effect of treatment on global health. In eRA, a significant imbalance in T CD4+ sub-types accompanied by increased levels of non-classical OCs precursors and pro-inflammatory cytokines was observed. A single dose of cholecalcipherol (300,000 IU) combined with standard treatment significantly ameliorates patients general health.

show abstract

Section: Resultsmentioning

confidence: 80%

Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study

Buondonno¹,

Rovera

Sassi³

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Кроме того, в своей работе они указали на отсутствие взаимосвязи между уровнем ФА и наличием аортальной кальцификации, связав последнюю с кумулятивной дозой ГК. Имеются единичные работы, в которых взаимосвязь между уровнем ФА и показателями активности РА обнаружена не была, что указывает на необходимость дальнейшего изучения данного вопроса [17,18]. Также следует отметить, что средний уровень ФА в группе условно здоровых лиц различался в данных исследованиях.…”

Section: Discussionunclassified

“…Так, в исследовании S. Ozturk и соавт. [13] Описана взаимосвязь уровня ФА c кумулятивной дозой ГК, но не со степенью активности РА [17,18]. В нашем исследовании 86 (78%) пациентов получали ГК в анамнезе, с медианой кумулятивной дозы -5760 [1900; 13 500] мг.…”

Section: Discussionunclassified

Serum Fetuin-a Levels in Patients With Rheumatoid Arthritis

Papichev¹,

Заводовский²,

Sivordova³

et al. 2019

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is the second most common rheumatic disease. In recent decades, there has been an active search for and study of biologically active substances involved in the pathogenesis of RA, which can serve as a starting point in designing new drugs for targeted therapy of this disease. The hepatokine fetuin-A (FA) is one of these substances.Objective: to investigate serum FA levels in patients with RA.Subjects and methods. The investigation enrolled 110 patients with RA. All the patients underwent the following set of studies: general blood test and determination of the serum levels of C-reactive protein (CRP), serum FA, rheumatoid factor, anti-cyclic citrullinated peptide (anti-CCP) antibodies, cartilage degradation products (CartiLaps), and urine creatinine. A control group consisted of 30 apparently healthy individuals whose serum FA level was determined in order to obtain reference values.Results and discussion. The normal FA level varied from 653.55 to 972.19 μg/ml. All the patients with RA were divided into two groups: 1) 23 patients with a low FA level (<653.55 μg/ml) and 2) 87 patients with a normal FA levels (≥653.55 μg/ml). The groups differed significantly in anti-CCP antibody concentrations, disease activity, radiological stages, functional classes, and the presence of complications. Patients with lower FA levels were noted to have increased CRP concentrations, erythrocyte sedimentation rate, and CartiLaps/urine creatinine ratio. The mean FA concentration was considerably and significantly lower in patients with higher DAS28 scores. Conclusion. Our investigation has revealed that there is a relationship between the levels of FA and the individual clinical manifestations of RA. The lower FA level is associated with higher disease activity and the aggressive phenotype of RA (the presence of anti-CCP antibodies, radiological stages III and IV, extra-articular manifestations and complications).

show abstract

“…Higher levels of this adipokine also correlate with inhibitory actions against adiponectin effects. Inflammation may also be driven by fetuin-A since it can activate TLR-4 and mimic the TGF-β receptor [ 118 , 119 , 147 ].…”

Section: General Aspects Of Ra and The Role Of Myokines Osteokines Ad...mentioning

confidence: 99%

Organokines in Rheumatoid Arthritis: A Critical Review

Laurindo

Maio

Barbalho

et al. 2022

IJMS

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily affects the joints. Organokines can produce beneficial or harmful effects in this condition. Among RA patients, organokines have been associated with increased inflammation and cartilage degradation due to augmented cytokines and metalloproteinases production, respectively. This study aimed to perform a review to investigate the role of adipokines, osteokines, myokines, and hepatokines on RA progression. PubMed, Embase, Google Scholar, and Cochrane were searched, and 18 studies were selected, comprising more than 17,000 RA patients. Changes in the pattern of organokines secretion were identified, and these could directly or indirectly contribute to aggravating RA, promoting articular alterations, and predicting the disease activity. In addition, organokines have been implicated in higher radiographic damage, immune dysregulation, and angiogenesis. These can also act as RA potent regulators of cells proliferation, differentiation, and apoptosis, controlling osteoclasts, chondrocytes, and fibroblasts as well as immune cells chemotaxis to RA sites. Although much is already known, much more is still unknown, principally about the roles of organokines in the occurrence of RA extra-articular manifestations.

show abstract

Comparison of fetuin‐A and transforming growth factor beta 1 levels in patients with spondyloarthropathies and rheumatoid arthritis

Abstract: We conclude that Fetuin-A may be one of the steps that can be active in disease progression in axial SpA patients.

Cited by 12 publications

References 28 publications

Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study

Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study

Serum Fetuin-a Levels in Patients With Rheumatoid Arthritis

Organokines in Rheumatoid Arthritis: A Critical Review

Contact Info

Product

Resources

About